NASDAQ:AQXP - Aquinox Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.65 -0.06 (-2.21 %) (As of 07/15/2018 04:00 PM ET)Previous Close$2.65Today's Range$2.58 - $2.7152-Week Range$1.96 - $16.90Volume963,694 shsAverage Volume1.86 million shsMarket Capitalization$62.30 millionP/E Ratio-1.24Dividend YieldN/ABeta-14.08 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive AQXP News and Ratings via Email Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AQXP CUSIPN/A Webwww.aqxpharma.com Phone604-629-9223 Debt Debt-to-Equity RatioN/A Current Ratio10.08 Quick Ratio10.08 Price-To-Earnings Trailing P/E Ratio-1.24 Forward P/E Ratio-1.31 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$4.21 per share Price / Book0.63 Profitability EPS (Most Recent Fiscal Year)($2.14) Net Income$-50,180,000.00 Net MarginsN/A Return on Equity-53.37% Return on Assets-49.03% Miscellaneous Employees51 Outstanding Shares23,510,000Market Cap$62.30 Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions What is Aquinox Pharmaceuticals' stock symbol? Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP." How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) released its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.08. View Aquinox Pharmaceuticals' Earnings History. When is Aquinox Pharmaceuticals' next earnings date? Aquinox Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Aquinox Pharmaceuticals. What price target have analysts set for AQXP? 4 brokers have issued 1 year price targets for Aquinox Pharmaceuticals' stock. Their predictions range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' share price to reach $25.25 in the next twelve months. This suggests a possible upside of 852.8% from the stock's current price. View Analyst Ratings for Aquinox Pharmaceuticals. What is the consensus analysts' recommendation for Aquinox Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquinox Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Aquinox Pharmaceuticals stock? Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock: 1. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (7/2/2018) 2. Cantor Fitzgerald analysts commented, ": We are downgrading our opinion of AQXP stock from and we are lowering our PT from $28 to $2. LEADERSHIP-301 trial and the decision to discontinue all rosiptor development leaves the company with little value other than cash, in our opinion." (6/27/2018) 3. Needham & Company LLC analysts commented, "Aquinox reported 1Q18 financial results today and we spoke with mgmt for an update. The rosiptor Phase 3 LEADERSHIP trial in Interstitial Cystitis (IC)/ Bladder Pain Syndrome (BPS) remains on track for top-line results in 3Q18, most likely in July. 12wk trial was completed in Feb 2018. We expect a positive outcome based on Phase 2 data. Mgmt plans to revisit Phase 3 design w/ FDA prior to initiation of a planned second Phase 3 trial, which we believe may begin around YE18. Patient screening in a Phase 2 trial of rosiptor in Chronic Prostatitis (CP/ CPPS) is underway. Reiterate BUY. We do not believe the stock adequately reflects value of rosiptor program in BPS/IC." (5/8/2018) 4. Canaccord Genuity analysts commented, "We recently hosted a call with Dr. J. Quentin Clemens, chief of the Division of Neurourology and Pelvic Reconstruction, urology director for female pelvic medicine and professor of urology at the University of Michigan. While Dr. Clemens has not used AQXP’s rosiptor (AQX-1125), his discussion of IC/BPS provided us with more confidence in the design of the ongoing, pivotal Ph3 LEADERSHIP 301 assessing rosiptor in IC/BPS patients, which remains on track to complete enrollment in 1Q18 and for top-line data in 3Q18. We reiterate our BUY rating." (12/19/2017) Who are some of Aquinox Pharmaceuticals' key competitors? Some companies that are related to Aquinox Pharmaceuticals include Galectin Therapeutics Inc. Common Stock (GALT), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Ocular Therapeutix (OCUL), Galmed Pharmaceuticals (GLMD), CTI BioPharma (CTIC), Cue Biopharma (CUE), MannKind (MNKD), REDHILL BIOPHAR/S (RDHL), Chimerix (CMRX), Kamada (KMDA), ProQR Therapeutics (PRQR), Immune Design (IMDZ), Ardelyx (ARDX), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) and Sierra Oncology (SRRA). Who are Aquinox Pharmaceuticals' key executives? Aquinox Pharmaceuticals' management team includes the folowing people: Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 53)Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 44)Mr. Lloyd Mackenzie, COO & VP of R&D Operations (Age 51)Ms. Shelley McCloskey, VP of HR & Admin. (Age 58)Mr. Paul Anthony Brennan, VP of Bus. Devel. Has Aquinox Pharmaceuticals been receiving favorable news coverage? News articles about AQXP stock have trended somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also assigned headlines about the company an impact score of 45.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. How do I buy shares of Aquinox Pharmaceuticals? Shares of AQXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aquinox Pharmaceuticals' stock price today? One share of AQXP stock can currently be purchased for approximately $2.65. How big of a company is Aquinox Pharmaceuticals? Aquinox Pharmaceuticals has a market capitalization of $62.30 million. The company earns $-50,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Aquinox Pharmaceuticals employs 51 workers across the globe. How can I contact Aquinox Pharmaceuticals? Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected] MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 217 (Vote Outperform)Underperform Votes: 158 (Vote Underperform)Total Votes: 375MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?